by Truveta Research | Jul 30, 2026 | Featured research, Research
During July 2026, the rate of cyclosporiasis diagnosis reached 10.5 per 100,000 people with a healthcare encounter, more than 11-fold higher than the average July rate observed between 2018 and 2025 (0.9 per 100,000). More than 1 in 5 patients with a cyclosporiasis...
by Truveta staff | Jul 29, 2026 | Research
Authors: Swapna Abhyankay, MD ⊕Truveta, Inc, Bellevue, WA, Rajesh M Rao, MS ⊕Truveta, Inc, Bellevue, WA, Mehraveh Salehi, PhD ⊕Truveta, Inc, Bellevue, WA, Jennifer J Liang, MD ⊕Truveta, Inc, Bellevue, WA, Jamalynne Deckard, MS ⊕Truveta, Inc, Bellevue, WA, Sujatha...
by Truveta Research | Jul 21, 2026 | Research
Authors: Patrica J Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Jay B Lusk, MD, MBA ⊕University of North Caroline-Chapel Hill, Chapel Hill, NC, Hemalkumar Mehta, PhD ⊕Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, Joseph F Levy, PhD ⊕Johns...
by Truveta Research | Jul 20, 2026 | Research
More than 8% of all prescriptions in June 2026 were for GLP-1 RAs, increasing slightly (+5.6%) since March 2026. Tirzepatide remained the leading anti-obesity medication (AOM) and anti-diabetic medication (ADM) by prescription volume and showed the largest increase in...
by Truveta Research | Jul 20, 2026 | Featured research, Research
More than 2 in 5 patients (40.3%) initiating oral orforglipron (Foundayo pill) had no prior evidence of GLP-1-based medication use, suggesting early uptake extends beyond patients already receiving injectable therapies. Among patients with prior GLP-1-based medication...
by Truveta staff | Jul 9, 2026 | Research
A study from University of Pittsburgh and Lumbrita used Truveta Data to compare mortality risk across four antipsychotics commonly used off label to treat Alzheimer’s disease. Among 17,004 patients with Alzheimer’s disease, mortality risk differed across medications...
